Our Pricing

Mounjaro Price Comparison: Finding the Right Weight Loss Treatment in the UK

Published on: June 03, 2026

When conducting a mounjaro price comparison uk pharmacy search, transparent upfront pricing matters. At Cured Pharmacy, Mounjaro (tirzepatide) KwikPen injections start from £124.99, with all costs shown before your free clinical consultation. Our UK-registered prescribers assess your suitability for Mounjaro alongside alternative treatments, ensuring you receive the most appropriate option for your weight loss journey.

Understanding Mounjaro: The UK's Newest Weight Loss Treatment

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, producing enhanced metabolic effects that support significant weight reduction.

In the SURMOUNT-1 clinical trial, participants receiving the 15mg tirzepatide dose achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. This dual-action mechanism distinguishes Mounjaro from earlier GLP-1-only treatments, though individual results vary and all prescription treatments require ongoing clinical supervision.

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen device. Dosing starts at 2.5mg weekly and gradually escalates over 16-20 weeks to a maintenance dose, typically 5mg, 10mg, or 15mg depending on individual response and tolerability [2]. Your UK prescriber determines the appropriate dose escalation schedule during your treatment journey.

Mounjaro Price Comparison UK Pharmacy: What Affects Cost

Mounjaro pricing in the UK varies significantly between providers, influenced by several factors including dose strength, supply chain relationships, and service models. At Cured Pharmacy, transparent pricing starts from £135.00 for genuine UK-licensed Mounjaro KwikPens, with the final cost determined by your prescribed maintenance dose following clinical assessment.

Unlike some providers who display estimated ranges or require consultation before revealing costs, Cured Pharmacy shows upfront pricing for all weight loss treatments. This transparency allows you to compare options meaningfully before committing to a clinical assessment. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures all dispensed medications meet MHRA licensing standards and originate from verified UK supply chains.

Pricing considerations extend beyond the medication itself. Reputable UK pharmacies include clinical consultation, prescriber review, discreet packaging, and ongoing treatment monitoring within their service. At Cured Pharmacy, your free online consultation takes under three minutes and connects you with UK-registered prescribers who assess suitability for Mounjaro and alternative treatments based on your medical history and weight loss goals.

Hidden Costs to Watch For

When comparing providers, examine the total service cost beyond the medication price alone. Some pharmacies charge separately for consultations, follow-up reviews, or delivery, which can substantially increase your overall expenditure. Cured Pharmacy includes clinical assessment, prescriber review, and discreet UK delivery in our transparent pricing structure, ensuring no unexpected charges during your treatment journey.

Mounjaro vs Wegovy: Clinical Differences and Cost Considerations

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are MHRA-licensed injectable treatments for weight management, but they operate through distinct mechanisms. Wegovy activates GLP-1 receptors exclusively, whilst Mounjaro's dual GIP/GLP-1 action produces different metabolic effects [3]. Head-to-head comparisons suggest tirzepatide may produce greater average weight reduction, though individual responses vary considerably.

In the SURMOUNT-1 trial, participants on 15mg tirzepatide lost an average of 22.5% body weight over 72 weeks [1]. The STEP 1 trial showed participants on 2.4mg semaglutide (Wegovy's maximum dose) achieved an average 14.9% weight reduction over 68 weeks [4]. These are average trial results; real-world outcomes depend on adherence, lifestyle modifications, and individual metabolic factors.

Both treatments require once-weekly subcutaneous injection and gradual dose escalation. Wegovy starts at 0.25mg weekly and increases to a maximum 2.4mg maintenance dose, whilst Mounjaro begins at 2.5mg and may escalate to 15mg depending on clinical response [2][3]. Your UK prescriber determines which treatment suits your medical profile, considering factors like previous GLP-1 experience, cardiovascular history, and treatment goals.

Which Treatment Offers Better Value?

Cost-effectiveness depends on individual clinical response rather than price alone. Whilst Wegovy may have lower starting costs at some providers, the most suitable treatment is the one that produces sustainable results with manageable side effects for your specific circumstances. Our UK prescribers assess both options during your consultation, recommending the treatment most likely to support your weight loss goals based on clinical evidence and your medical history.

Alternative Weight Loss Treatments Available at Cured Pharmacy

Beyond Mounjaro and Wegovy, several MHRA-licensed weight loss treatments suit different clinical needs and budgets. Saxenda (liraglutide) is a daily GLP-1 injection that predates once-weekly alternatives, offering an established safety profile for patients who prefer more frequent dosing or have previously responded well to liraglutide [5].

Oral treatments like Orlistat (available as generic, Xenical, Alli, or Orlos) work through a completely different mechanism, blocking approximately 30% of dietary fat absorption in the digestive system [6]. Orlistat suits patients who prefer tablets over injections or have contraindications to GLP-1 treatments, though it requires strict dietary adherence to minimise gastrointestinal side effects.

The newly available Wegovy oral tablets (semaglutide pill) provide a non-injectable GLP-1 option for patients who find injections challenging. This formulation uses absorption-enhancing technology to deliver semaglutide orally, offering comparable efficacy to the injectable version in clinical trials [7]. Your UK prescriber discusses all suitable options during your consultation, considering your preferences, medical history, and treatment goals.

How to Start Your Mounjaro Treatment at Cured Pharmacy

Beginning treatment requires a clinical assessment by a UK-registered prescriber, as Mounjaro is a prescription-only medication under MHRA regulations. At Cured Pharmacy, the process starts with a free online consultation taking under three minutes, where you provide medical history, current medications, and weight loss goals through our secure platform.

Our UK prescribers review your assessment within hours, determining whether Mounjaro or an alternative treatment suits your clinical profile. If Mounjaro is appropriate, your prescriber specifies the starting dose and escalation schedule. If contraindications exist or another treatment offers better suitability, they recommend alternatives like Wegovy, Saxenda, or Orlistat based on clinical evidence.

Once approved, your prescription is dispensed by our GPhC-registered pharmacy (9012511) and dispatched in 100% discreet packaging with tracked delivery. Follow-up consultations monitor your progress, adjust dosing as needed, and address any side effects. Ongoing prescriber support ensures safe, effective treatment throughout your weight loss journey, with the flexibility to modify your treatment plan based on clinical response.

What Happens During Your Clinical Assessment

Your online consultation collects essential information including current BMI, previous weight loss attempts, existing medical conditions, and medications that might interact with GLP-1 treatments. UK prescribers assess cardiovascular history, thyroid conditions, and family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as these may contraindicate Mounjaro use [2]. This thorough assessment ensures patient safety and treatment appropriateness before any prescription is issued.

Maximising Results: What to Expect from Mounjaro Treatment

Clinical trials demonstrate Mounjaro's efficacy when combined with reduced-calorie diet and increased physical activity, not as a standalone solution [1]. Average weight loss occurs gradually over 72 weeks, with most significant reductions appearing after reaching maintenance dose. Individual results vary considerably based on adherence, baseline BMI, metabolic factors, and lifestyle modifications implemented alongside medication.

Common side effects during dose escalation include nausea, diarrhoea, decreased appetite, and constipation, typically diminishing as your body adapts [2]. Starting at a low dose and escalating gradually minimises these effects whilst allowing your metabolism to adjust. Approximately 5-10% of patients discontinue treatment due to gastrointestinal side effects, though most find these manageable with dietary adjustments and hydration.

Long-term success requires ongoing treatment and lifestyle maintenance. Clinical data shows weight regain commonly occurs after discontinuing GLP-1 treatments, emphasising the importance of sustainable dietary and exercise habits developed during treatment [8]. Your UK prescriber provides guidance on nutrition, physical activity, and behavioural strategies that support lasting weight management beyond medication alone.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/14881 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
7. Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6 [accessed 13 August 2026]
8. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and are not guaranteed.